한국어
Quantus

Yungjin Pharm.

003520 · KOSPI
₩1,116+0.36%
2026-09-04 close

Yungjin Pharm. last closed at ₩1,116 (+0.36%) on 2026-09-04. Listed on KOSPI; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

F
Overall: 건강관리 262/291 · top 90%
Factor composite · relative position in sector

PER 165.57 · PBR 2.27 — own-history percentile 90/100 · 92/100

Open self-history band
PER90/100
PBR92/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 0.86
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
0.86
Beneish M-Score
-2.97

No statistical flag

Sloan accrual
-8.75%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 성장 + 마진 확대 + FCF 양수

Positive

매출이 +7.3% 성장하면서 영업이익률이 -0.4%에서 2.7%로 확대되었다. FCF도 양수를 유지하여 질적 성장이 확인된다.

Evidence

매출 YoY +7.3%영업이익률 -0.4%→2.7%FCF 43,348

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

7/9Strong

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score7/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Margin trendWarning

영업외손익 급변 (영업이익 대비 38% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 52 of 287, share 0.4%.

52 / 2870.4%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6영진약품0.4%

Concentration

DistributedCR3 16.6%
HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
13.9
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
2.7%
Interest coverage
1.1x
Return on equity (ROE)
1.4%

Operating margin −5pp

Operating loss
Interest coverageBase 1.1x adverse case -0.9x
Return on equity (ROE)Base 1.4% adverse case -13.2%

Revenue −15%

Interest coverage risk
Interest coverageBase 1.1x adverse case 0.9x
Return on equity (ROE)Base 1.4% adverse case -0.3%

Interest rate +2pp

Interest coverage risk
Interest coverageBase 1.1x adverse case 0.8x
Return on equity (ROE)Base 1.4% adverse case -2.4%

Interest coverage limit

Current margin 0.3pp

Interest coverage limit at an operating margin of 2.4%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-12

Suppliers disclosed by the company in its 2026-03-12 annual report.

Purchase amount

KRW 100m
  1. Sumitomo
    KRW 2.2T
  2. Ceftriaxone
    KRW 354.9B
  3. Hydrate
    KRW 354.9B
  4. Sodium
    KRW 354.9B
  5. 제일약품Price comovement r=0.22 (1 year)
    KRW 354.9B
  6. 경보제약Price comovement r=0.17 (1 year)
    KRW 299.7B
  7. MAC
    KRW 174.1B
  8. Haoyun
    KRW 145.9B
  9. HCl
    KRW 145.9B
  10. Heilongjiang
    KRW 145.9B

+6 more with disclosed amounts — included in coverage

Suppliers without disclosed amount

CMZJPYUSDKRW

Connections

AI-extracted related companies · for reference

Customers
서울아산병원삼성서울병원세브란스병원
Same theme
테마: 제네릭의약품테마: 전문의약품
🔗 See in the full market map →

Recent filings

Yungjin Pharm.'s latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About Yungjin Pharm.
What technical signals does Yungjin Pharm. (003520) have?
Yungjin Pharm. current technical signals: no active technical signal.
Is Yungjin Pharm. a cup-and-handle pattern?
No. Yungjin Pharm. has no valid cup-and-handle signal right now.
What are Yungjin Pharm.'s financials and valuation?
Yungjin Pharm.'s income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy